Research Article
Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Table 3
Univariate and multivariate analysis of PFS in patients treated with immune checkpoint inhibitors.
| Baseline characteristics | Median PFS (95% CI) | value (univariate analysis) | HR (95% CI) | value (multivariate analysis) |
| Ages (years) | | 0.250 | | | <65 | 13.20 (9.173–17.227) | | | | ≥65 | 14.80 (10.526–19.074) | | | | Sex | | 0.224 | | | Male | 12.10 (7.401–16.799) | | | | Female | 16.20 (13.223–19.177) | | | | Therapy lines | | 0.096 | | | First-line | 15.10 (14.567–15.633) | | 0.604 (0.383–0.955) | 0.031 | Second or more-line | 8.60 (5.248–11.952) | | Smoking history | | 0.010 | | | Never-smoker | 15.40 (14.114–16.686) | | 1.976 (1.247–3.133) | 0.004 | Current or ex-smoker | 8.60 (4.161–13.039) | | Histology | | 0.688 | | | Nonsquamous | 13.20 (9.001–17.399) | | | | Squamous | 14.10 (11.276–16.924) | | | | Pathological staging | | 0.323 | | | III | 6.60 (0.000–13.417) | | | | IV | 14.10 (11.589–16.611) | | | | Presence of treating with antibiotic during immunotherapy | | 0.754 | | | Yes | 11.20 (6.271–16.129) | | | | No | 14.70 (10.299–19.101) | | | | Presence of serious AEs | | 0.749 | | | Yes | 11.20 (2.929–19.471) | | | | No | 14.10 (10.882–17.318) | | | | Presence of irAEs | | 0.504 | | | Yes | 15.40 (10.657–17.143) | | | | No | 13.20 (10.191–16.209) | | | |
|
|